P17 Dissection of the molecular and cellular heterogeneity of dermal fibroblasts in skin fibrosis

Abstract

Abstract Introduction and aims Skin fibrosis, a common fibrotic condition that currently has no specific treatments or cures, is caused by persistent activation of skin fibroblasts after tissue injury that Results in excessive scarring, can cause severe disability and seriously affect morbidity. This study aims to uncover the specific fibroblast subsets and molecular pathways that are integral to this sustained fibroblast activation using a bleomycin-induced skin fibrosis mouse model that accurately recapitulates the human disease. Methods We have successfully shown that 2 weeks (early) and 4 weeks (advanced) of bleomycin injections Results in an increasing severity of skin fibrosis characteristics. Following this treatment, we performed single-cell RNA sequencing (scRNA-Seq) using control, early and advanced fibrotic tissue and identified fibroblast subclusters and specific gene signatures that are altered across the time course and may play a role in the fibrotic phenotype we observe. The use of advanced scRNA-Seq analysis techniques such as SCENIC and regulon analysis has allowed us to further characterize the changes in fibroblast states during fibrosis. Results Our scRNA-Seq data show a loss of fibroblast heterogeneity alongside the emergence of two main subclusters with distinct gene signatures in the advanced fibrotic state. While proliferation is minimal, RNA velocity analysis indicates that the increase in cell count is due to the convergence of neighbouring fibroblast subclusters. The pronounced profibrotic gene expression point to its key role in driving skin fibrosis and we are now exploring the therapeutic potential of chemically or genetically targeting this subcluster. Conclusions Our novel skin fibrosis time course scRNA-Seq dataset allows us to compare the cellular and molecular changes in early and advanced fibrotic lesions in order to identify the key fibroblast subpopulations, molecular regulators and connective tissue alterations promoting fibrotic tissue repair. Our findings will support the development of new fibroblast-targeted fibrosis therapies in skin and potentially in other organs.